Skip to main content

In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding.

Publication ,  Journal Article
Tannu, M; Newby, LK
Published in: Ann Intern Med
November 2023

Gragnano F, Cao D, Pirondini L, et al; PANTHER Collaboration. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol. 2023;82:89-105. 37407118.

Duke Scholars

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

November 2023

Volume

176

Issue

11

Start / End Page

JC123

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Purinergic P2Y Receptor Antagonists
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Humans
  • Hemorrhage
  • General & Internal Medicine
  • Drug Therapy, Combination
  • Aspirin
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tannu, M., & Newby, L. K. (2023). In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding. Ann Intern Med, 176(11), JC123. https://doi.org/10.7326/J23-0090
Tannu, Manasi, and L Kristin Newby. “In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding.Ann Intern Med 176, no. 11 (November 2023): JC123. https://doi.org/10.7326/J23-0090.
Tannu, Manasi, and L. Kristin Newby. “In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding.Ann Intern Med, vol. 176, no. 11, Nov. 2023, p. JC123. Pubmed, doi:10.7326/J23-0090.

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

November 2023

Volume

176

Issue

11

Start / End Page

JC123

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Purinergic P2Y Receptor Antagonists
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Humans
  • Hemorrhage
  • General & Internal Medicine
  • Drug Therapy, Combination
  • Aspirin
  • 3202 Clinical sciences